Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 50Lymphoma 6Recurrence 3Waldenstrom Macroglobulinemia 2Plasmacytoma 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Acute 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Neoplasms 2Amyloidosis 2Smoldering Multiple Myeloma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1POEMS Syndrome 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Hematologic Diseases 1Graft vs Host Disease 1Glioblastoma 1Chromosome 17 deletion 1Alzheimer Disease 1Advanced Non-hematologic Malignancies 1Advanced Cancers 1

Interventions

Surveys and Questionnaires 3pazopanib 2Oxaliplatin 2Erlotinib Hydrochloride 2Cetuximab 2Bevacizumab 2satraplatin 1ixazomib 1Vorinostat 1Videotape Recording 1Valproic Acid 1Trastuzumab 1Platinum 1Leucovorin 1Lapatinib 1LY 2275796 1Fluorouracil 1Everolimus 1Capecitabine 1Azacitidine 1Albumin-Bound Paclitaxel 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Cancers × ixazomib × Clear all
NCT02042989 2022-07-11

MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
68 enrolled

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡